Point: Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging.

OBJECTIVE There is an increase in interest in limited resection for clinical stage IA non-small cell lung cancer. The purpose of this study was to evaluate the accuracy of the diagnosis of clinical stage IA non-small cell lung cancer when determined by both computed tomography and positron emission tomography scans and to determine factors associated with understaging. METHODS A retrospective review of a prospectively maintained database of patients with non-small cell lung cancer was performed. Patients with clinical stage IA cancer determined by preoperative computed tomography and positron emission tomography scan were reviewed. The influence of the following factors was analyzed with regard to accuracy of clinical staging: tumor size, location, histology, and positron emission tomography positivity. RESULTS Of the 266 patients identified, cancer was correctly staged in 65%. Final pathologic stages also included IB (15%), IIA (2.6%), IIB (4.1%), IIIA (4.9%), IIIB (7.5%), and IV (.08%). Positive lymph nodes were found in 11.7% of patients. Pathologic T classification changed in 28.2% of patients. Cancer in patients with clinical tumor size greater than 2 cm (n = 68) was significantly more likely to be understaged than in patients with tumors 2 cm or less (49% vs 29%, P = .003). Cancer in patients with a positron emission tomography-positive (positron emission tomography +VE) primary evaluation (n = 218) was also more likely to be understaged (39% vs 15%, P = .001). Of patients with positron emission tomography +VE tumors greater than 2 cm, cancer was clinically understaged in 55%, compared with 32% for positron emission tomography +VE tumors 2 cm or less, and only 17% for positron emission tomography negative (-VE) tumors less than 2 cm. CONCLUSION Clinical stage IA lung cancer is frequently understaged in patients. Size greater than 2 cm and positron emission tomography positivity are risk factors for understaging. Limited resection should be undertaken with caution in such patients.

[1]  M. Graham,et al.  Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer? , 2002, The Annals of thoracic surgery.

[2]  Robert D Timmerman,et al.  The North American Experience with Stereotactic Body Radiation Therapy in Non-small Cell Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  G. V. von Schulthess,et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.

[4]  G. Patterson,et al.  Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial. , 2005, Lung cancer.

[5]  G. Hobbs,et al.  Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. , 2001, Chest.

[6]  Max Lonneux,et al.  Prognostic value of FDG uptake in early stage non-small cell lung cancer. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[7]  Y. Kitayama,et al.  Peripheral lung adenocarcinomas: 10 mm or less in diameter. , 2003, The Annals of thoracic surgery.

[8]  P. Valk,et al.  Factors associated with false-positive staging of lung cancer by positron emission tomography. , 2000, The Annals of thoracic surgery.

[9]  Byung-Tae Kim,et al.  Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. , 2005, Radiology.

[10]  M. Okada,et al.  Characteristics and prognosis of patients after resection of nonsmall cell lung carcinoma measuring 2 cm or less in greatest dimension , 2003, Cancer.

[11]  H. Wada,et al.  A new method of segmental resection for primary lung cancer: intermediate results. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[12]  R. Coleman,et al.  A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. , 2003, The Journal of thoracic and cardiovascular surgery.

[13]  F. Gao,et al.  Prognostic Value of Preoperative Positron Emission Tomography in Resected Stage I Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  L V Rubinstein,et al.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. , 1995, The Annals of thoracic surgery.

[15]  R. Cerfolio,et al.  The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. , 2005, The Journal of thoracic and cardiovascular surgery.

[16]  Improved Radiologic Staging of Lung Cancer with 2-[18F]-Fluoro-2-Deoxy-d-Glucose–Positron Emission Tomography and Computed Tomography Registration , 2003, Journal of computer assisted tomography.

[17]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[18]  N. Altorki,et al.  Tumor size is a determinant of stage distribution in t1 non-small cell lung cancer. , 2005, Chest.

[19]  V. Rusch,et al.  Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. , 2003, The Journal of thoracic and cardiovascular surgery.

[20]  N. Altorki,et al.  Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. , 2007, The Annals of thoracic surgery.

[21]  H. Asamura,et al.  Prognostic significance of pleural lavage cytology immediately after thoracotomy in patients with lung cancer. , 1993, The Journal of thoracic and cardiovascular surgery.

[22]  A. Dujon,et al.  Visceral pleura invasion by non-small cell lung cancer: an underrated bad prognostic factor. , 2001, The Annals of thoracic surgery.

[23]  P. Goldstraw,et al.  The accuracy of clinical evaluative intrathoracic staging in lung cancer as assessed by postsurgical pathologic staging , 1990, Cancer.

[24]  Elisabeth Brambilla,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  D. Harpole,et al.  Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence , 1995, Cancer.

[26]  D. Wood,et al.  The impact of fluorodeoxyglucose F 18 positron-emission tomography on the surgical staging of non-small cell lung cancer. , 2002, The Journal of thoracic and cardiovascular surgery.

[27]  G. Patterson,et al.  Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. , 2006, The Journal of thoracic and cardiovascular surgery.

[28]  J. Crowley,et al.  Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. , 2000, The Journal of thoracic and cardiovascular surgery.

[29]  J. Luketich,et al.  Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis. , 2006, The Annals of thoracic surgery.

[30]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  Yu-Chung Wu,et al.  Prognostic factors in resected stage I non-small cell lung cancer with a diameter of 3 cm or less: visceral pleural invasion did not influence overall and disease-free survival. , 2007, The Journal of thoracic and cardiovascular surgery.

[32]  R. Cerfolio,et al.  Improving the inaccuracies of clinical staging of patients with NSCLC: a prospective trial. , 2005, The Annals of thoracic surgery.

[33]  K. Honma,et al.  Lymph node metastasis in small peripheral adenocarcinoma of the lung. , 1998, The Journal of thoracic and cardiovascular surgery.